{"id":49152,"date":"2025-11-27T20:57:30","date_gmt":"2025-11-27T12:57:30","guid":{"rendered":"https:\/\/flcube.com\/?p=49152"},"modified":"2025-11-27T20:57:31","modified_gmt":"2025-11-27T12:57:31","slug":"iaso-bios-fucaso-wins-hong-kong-approval-as-first-china-car-t","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=49152","title":{"rendered":"IASO-Bio&#8217;s Fucaso Wins Hong-Kong Approval as First China CAR-T"},"content":{"rendered":"\n<p><strong>IASO Biotherapeutics<\/strong> announced that <strong>Fucaso (equecabtagene autoleucel injection)<\/strong>, its proprietary <strong>fully human BCMA\u2011targeted CAR\u2011T cell therapy<\/strong>, received marketing approval from the <strong>Hong Kong Department of Health<\/strong> for adult patients with <strong>relapsed or refractory multiple myeloma (R\/R MM)<\/strong> after at least three prior lines of therapy, marking the <strong>first China\u2011developed CAR\u2011T<\/strong> approved in Hong Kong.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Fucaso (equecabtagene autoleucel)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>IASO Bio<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>Hong Kong Department of Health<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Marketing authorization<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>R\/R MM after \u22653 prior lines<\/td><\/tr><tr><td><strong>China Approval<\/strong><\/td><td>NMPA approved July\u202f2023 for same indication<\/td><\/tr><tr><td><strong>Manufacturing<\/strong><\/td><td>First domestically produced ATMP with <strong>PIC\/S GMP certification<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile\">Drug Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> BCMA\u2011directed CAR\u2011T using <strong>lentiviral vector<\/strong> to transfect autologous T cells<\/li>\n\n\n\n<li><strong>CAR Construct:<\/strong> Fully human scFv, CD8\u03b1 hinge\/transmembrane, <strong>4\u20111BB co\u2011stimulatory<\/strong>, CD3\u03b6 activation domain<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> <strong>Fully human scFv<\/strong> reduces immunogenicity risk vs. murine\u2011derived CAR\u2011Ts<\/li>\n\n\n\n<li><strong>Certification:<\/strong> PIC\/S GMP certification positions IASO for <strong>global supply<\/strong> and partnership opportunities<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-outlook\">Market Context &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><\/tr><\/thead><tbody><tr><td><strong>Hong Kong MM Incidence<\/strong><\/td><td>~300 new cases annually<\/td><\/tr><tr><td><strong>R\/R MM Patients Eligible<\/strong><\/td><td>~120 patients (40% of total)<\/td><\/tr><tr><td><strong>CAR\u2011T Market Size (HK)<\/strong><\/td><td>HK$150\u2011200\u202fmillion (US$19\u201126\u202fmillion)<\/td><\/tr><tr><td><strong>Pricing<\/strong><\/td><td>Expected HK$1.2\u20111.5\u202fmillion per dose (aligned with mainland China pricing)<\/td><\/tr><tr><td><strong>Peak Sales Forecast<\/strong><\/td><td><strong>HK$80\u2011100\u202fmillion<\/strong> (~US$10\u201113\u202fmillion) by 2028<\/td><\/tr><tr><td><strong>Strategic Value<\/strong><\/td><td>Gateway to <strong>Southeast Asia<\/strong> and <strong>global markets<\/strong> via Hong Kong\u2019s regulatory credibility<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Competitive Edge:<\/strong> <strong>First\u2011mover advantage<\/strong> in Hong Kong; no other BCMA CAR\u2011Ts approved locally<\/li>\n\n\n\n<li><strong>Next Catalysts:<\/strong> Potential <strong>Japan PMDA filing<\/strong> Q2\u202f2026; <strong>U.S. IND<\/strong> under discussion with FDA<\/li>\n\n\n\n<li><strong>Manufacturing Scale:<\/strong> PIC\/S certification enables export to <strong>PIC\/S member countries<\/strong> (85+ nations)<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Fucaso\u2019s commercial launch in Hong Kong, global expansion plans, and manufacturing capabilities. Actual results may differ materially due to risks including market adoption, competitive responses, and regulatory changes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>IASO Biotherapeutics announced that Fucaso (equecabtagene autoleucel injection), its proprietary fully human BCMA\u2011targeted CAR\u2011T cell&#8230;<\/p>\n","protected":false},"author":1,"featured_media":49153,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[594],"class_list":["post-49152","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-iaso-biotherapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>IASO-Bio&#039;s Fucaso Wins Hong-Kong Approval as First China CAR-T - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"IASO Biotherapeutics announced that Fucaso (equecabtagene autoleucel injection), its proprietary fully human BCMA\u2011targeted CAR\u2011T cell therapy, received marketing approval from the Hong Kong Department of Health for adult patients with relapsed or refractory multiple myeloma (R\/R MM) after at least three prior lines of therapy, marking the first China\u2011developed CAR\u2011T approved in Hong Kong.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=49152\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IASO-Bio&#039;s Fucaso Wins Hong-Kong Approval as First China CAR-T\" \/>\n<meta property=\"og:description\" content=\"IASO Biotherapeutics announced that Fucaso (equecabtagene autoleucel injection), its proprietary fully human BCMA\u2011targeted CAR\u2011T cell therapy, received marketing approval from the Hong Kong Department of Health for adult patients with relapsed or refractory multiple myeloma (R\/R MM) after at least three prior lines of therapy, marking the first China\u2011developed CAR\u2011T approved in Hong Kong.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=49152\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-27T12:57:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-27T12:57:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2701-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49152#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49152\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"IASO-Bio&#8217;s Fucaso Wins Hong-Kong Approval as First China CAR-T\",\"datePublished\":\"2025-11-27T12:57:30+00:00\",\"dateModified\":\"2025-11-27T12:57:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49152\"},\"wordCount\":318,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49152#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2701-1.webp\",\"keywords\":[\"IASO Biotherapeutics\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49152#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49152\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=49152\",\"name\":\"IASO-Bio's Fucaso Wins Hong-Kong Approval as First China CAR-T - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49152#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49152#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2701-1.webp\",\"datePublished\":\"2025-11-27T12:57:30+00:00\",\"dateModified\":\"2025-11-27T12:57:31+00:00\",\"description\":\"IASO Biotherapeutics announced that Fucaso (equecabtagene autoleucel injection), its proprietary fully human BCMA\u2011targeted CAR\u2011T cell therapy, received marketing approval from the Hong Kong Department of Health for adult patients with relapsed or refractory multiple myeloma (R\\\/R MM) after at least three prior lines of therapy, marking the first China\u2011developed CAR\u2011T approved in Hong Kong.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49152#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49152\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49152#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2701-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2701-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"IASO-Bio's Fucaso Wins Hong-Kong Approval as First China CAR-T\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49152#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IASO-Bio&#8217;s Fucaso Wins Hong-Kong Approval as First China CAR-T\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"IASO-Bio's Fucaso Wins Hong-Kong Approval as First China CAR-T - Insight, China&#039;s Pharmaceutical Industry","description":"IASO Biotherapeutics announced that Fucaso (equecabtagene autoleucel injection), its proprietary fully human BCMA\u2011targeted CAR\u2011T cell therapy, received marketing approval from the Hong Kong Department of Health for adult patients with relapsed or refractory multiple myeloma (R\/R MM) after at least three prior lines of therapy, marking the first China\u2011developed CAR\u2011T approved in Hong Kong.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=49152","og_locale":"en_US","og_type":"article","og_title":"IASO-Bio's Fucaso Wins Hong-Kong Approval as First China CAR-T","og_description":"IASO Biotherapeutics announced that Fucaso (equecabtagene autoleucel injection), its proprietary fully human BCMA\u2011targeted CAR\u2011T cell therapy, received marketing approval from the Hong Kong Department of Health for adult patients with relapsed or refractory multiple myeloma (R\/R MM) after at least three prior lines of therapy, marking the first China\u2011developed CAR\u2011T approved in Hong Kong.","og_url":"https:\/\/flcube.com\/?p=49152","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-27T12:57:30+00:00","article_modified_time":"2025-11-27T12:57:31+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2701-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=49152#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=49152"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"IASO-Bio&#8217;s Fucaso Wins Hong-Kong Approval as First China CAR-T","datePublished":"2025-11-27T12:57:30+00:00","dateModified":"2025-11-27T12:57:31+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=49152"},"wordCount":318,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=49152#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2701-1.webp","keywords":["IASO Biotherapeutics"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=49152#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=49152","url":"https:\/\/flcube.com\/?p=49152","name":"IASO-Bio's Fucaso Wins Hong-Kong Approval as First China CAR-T - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=49152#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=49152#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2701-1.webp","datePublished":"2025-11-27T12:57:30+00:00","dateModified":"2025-11-27T12:57:31+00:00","description":"IASO Biotherapeutics announced that Fucaso (equecabtagene autoleucel injection), its proprietary fully human BCMA\u2011targeted CAR\u2011T cell therapy, received marketing approval from the Hong Kong Department of Health for adult patients with relapsed or refractory multiple myeloma (R\/R MM) after at least three prior lines of therapy, marking the first China\u2011developed CAR\u2011T approved in Hong Kong.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=49152#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=49152"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=49152#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2701-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2701-1.webp","width":1080,"height":608,"caption":"IASO-Bio's Fucaso Wins Hong-Kong Approval as First China CAR-T"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=49152#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"IASO-Bio&#8217;s Fucaso Wins Hong-Kong Approval as First China CAR-T"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2701-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49152","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49152"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49152\/revisions"}],"predecessor-version":[{"id":49154,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49152\/revisions\/49154"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/49153"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49152"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49152"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49152"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}